Table 2

Characteristics of samples used in this study grouped by responses of cells to Tipifarnib and GO: CD34+CD38-cells
AML# %CD34+CD38- CD123 MFI CD33 MFI Tip% cell loss1 GO%cell loss1 Tip/GO%cell loss1 Δtox2
#13 3 92 88 96 100 -
#19 3.4 20 1.4 66 91 100 -
#1 40 51 193 61 40 96 -
#10 7.6 12 0.5 80 26 94 -
#33 0.3 46 143 26 67 94 1
#4 1.7 35 437 57 57 93 -
#14 45 319 9.7 59 25 93 9
#32 33 62 51 0 45 92 47
#11 2.5 35 61 12 53 91 26
#9 0.3 34 13 32 57 90 1
#34 2.6 70 1.5 44 31 86 11
#16 2.3 1.8 92 0 59 81 22
#17 7 4.9 16 21 51 81 9
#8 17 53 72 0 0 73 73
#15 78 23 3.4 47 16 72 9
#5 16 76 74 0 60 70 10
#6 0.2 19 57 0 66 66 0
#20 2.4 173 31 11 43 64 10
#3 9 8.4 12 15 0 63 48
#35 3.7 9.2 7.2 62 1 62 −1
#31 0.8 55 9.6 41 38 52 −27
#26 2.4 17 9 43 0 43 0
#25 12 42 3.2 15 2 38 21
#18 85 20 1.9 0 8 33 25
#29 0.9 62 31 0 64 27 −37
#27 14 20 100 0 0 26 26
#2 54 20 3.1 6 5 18 7
#36 53 6 6.2 27 9 14 −22
#7 23 11 15 0 5 0 −5
#12 0.3 29 7.5 0 34 0 −34
#21 6.2 24 53 0 0 0 0
#23 0.2 4.2 20 0 2 0 −2
#28 6 17 3.2 0 0 0 0
#30 2.4 90 34 0 0 0 0

34 AML samples used in this study ordered by magnitude of response to tipifarnib + GO (column second from the right).

1% of cells lost after 48 hours treatment (compared to untreated control).

2 Δtox = cell loss with drug combination – (cell loss with tipifarnib + cell loss with GO). No values are displayed when cell loss with tipifarnib + cell loss with GO= > 100%.

Jawad et al.

Jawad et al. BMC Cancer 2012 12:431   doi:10.1186/1471-2407-12-431

Open Data